Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
about
Microvesicles as a potential biomarker of neoplastic diseases and their role in development and progression of neoplasmCancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screeningCancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screeningCancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screeningCancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screeningIdentification of five serum protein markers for detection of ovarian cancer by antibody arraysBiosensors Incorporating Bimetallic Nanoparticles.Molecular genetics complexity impeding research progress in breast and ovarian cancers.Intra-peritoneal hyperthermia combining α-galactosylceramide in the treatment of ovarian cancer.ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics.Nanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancer.Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.Microvesicles as potential ovarian cancer biomarkers.The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.Application of proteomics in the study of rodent models of cancer.Unexpected ovarian malignancy following laparoscopic excision of adnexal masses.microRNA and Ovarian Cancer.Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells.Cancer Screening and Early Detection in the 21st Century.Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides.Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City.Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression.Serum endocan levels in endometrial and ovarian cancers.Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Molecular Diagnostics in Clinical Oncology
P2860
Q26768704-80D71419-9730-4042-9DD8-1029C45A86D4Q26770123-86A3D259-DCEA-4813-8991-A20B8E289987Q26864419-82136336-43ED-4A97-B147-EB9EA977B7E7Q27001043-AB73FA8F-CE3E-4AE5-A9E6-9E7E77C3EF5DQ27025805-70BB2A16-05BD-44FA-A955-4F5E4D258E6DQ28534203-26204015-01BC-4786-B4FD-004A219A75B5Q29248731-4FC7A017-E85C-4D70-A4A4-5599B12555AEQ33858073-9031B083-B90A-4696-AEFA-2A3792631F3AQ34919851-8BB037E5-E131-471F-A537-3326B1DBD157Q35440069-94FE4676-720A-4418-A02D-6F92B51AC2BAQ35759283-73ABFAF5-20BC-4F41-AAB1-268CAD5399D5Q35848103-E45C336E-B467-4AC3-9E16-B3259E56A787Q35941858-BF11955A-1847-481E-A4A9-59FD069991D5Q36286844-4FF9A1E3-57F3-4573-B842-E4CE52B4B977Q36635032-B6DD30E3-590D-45AB-BFFA-43AA5BDEF917Q36820568-B17E1804-66A8-4B40-9F6F-8C096B356BB5Q38194543-A259E732-F968-40D1-A9AE-4C6AFA247A0EQ38223217-E464CB4D-D432-4F94-A528-A5DBDACF0309Q38667018-20C1FB92-DEF7-419A-9493-2C4F5D9E5BFBQ38844895-9BA76FB1-B0FF-4064-9BDA-F4E026B2CA07Q38875555-1F0B62C8-F1E3-49B2-ADDD-263E94977464Q39329143-8BB1F24C-CF8B-421D-BFAF-A0D440015C48Q41838773-4D3DCB5B-7E9E-4F35-89EE-DA4641188F98Q47124965-1BBFEF33-C9CA-433F-8AB5-AFA8EABA5AF3Q47134018-F091484F-754A-45E7-82F8-39AEBC2A01FBQ47982714-6370BF2F-094B-4D86-901B-64D4A25BD987Q48227450-D69AF2B2-3C0B-4E6C-A710-6964E5DFA301Q58700723-BD549E86-B00C-4513-A006-93B2010F83D6
P2860
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@ast
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@en
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@nl
type
label
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@ast
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@en
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@nl
prefLabel
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@ast
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@en
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@nl
P2093
P1476
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
@en
P2093
Eiji Kobayashi
Kiyoshi Yoshino
Masami Fujita
Tadashi Kimura
Takayuki Enomoto
Takuhei Yokoyama
Toshihiro Kimura
Yutaka Ueda
P304
P356
10.1158/1055-9965.EPI-12-0646
P577
2012-09-07T00:00:00Z